Table 2.
Atopy, asthma and lung function in late childhood in 586 Norwegian children according to mother’s preeclampsia status
| |
Severe preeclampsia |
Mild/moderate preeclampsia |
No preeclampsia |
Severe vs. no preeclampsia |
Mild/moderate vs. no preeclampsia |
Overall |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outcome variable | n | n | n | p-value a) | p-value a) | p-value b) | ||||||
|
FU1 variables |
|
|
|
|
|
|
|
|
|
|
|
|
| Allergic rhinoconjunctivitis, n (%) |
54 |
19 |
(35.2) |
161 |
36 |
(22.4) |
371 |
71 |
(19.1) |
0.018 |
0.822 |
0.015 |
| Atopic dermatitis, n (%) |
54 |
15 |
(27.8) |
163 |
37 |
(22.7) |
369 |
92 |
(24.9) |
1.476 |
1.172 |
1.000 |
| Asthma, n (%) |
53 |
9 |
(17.0) |
161 |
14 |
(8.7) |
366 |
30 |
(8.2) |
0.092 |
1.730 |
0.100 |
|
FU2 variables |
|
|
|
|
|
|
|
|
|
|
|
|
| Allergic sensitization, n (%) |
39 |
15 |
(38.5) |
112 |
40 |
(36.3) |
230 |
72 |
(31.3) |
0.918 |
0.924 |
0.296 |
| High level allergic sensitization, n (%)c) |
39 |
15 |
(38.5) |
112 |
28 |
(25.0) |
230 |
50 |
(21.7) |
0.056 |
1.166 |
0.042 |
| Current asthma, n (%) |
46 |
6 |
(13.0) |
123 |
12 |
(9.8) |
279 |
19 |
(6.8) |
0.454 |
0.630 |
0.126 |
| FEV1%, mean, 95% CI |
45 |
89.7 |
(87.0, 92.5) |
126 |
91.0 |
(89.0, 93.0) |
272 |
91.1 |
(90.0, 92.2) |
1.000 |
1.000 |
0.682 |
| FVC%, mean, 95% CI |
45 |
99.2 |
(95.5, 102.8) |
126 |
100.0 |
(97.7, 102.3) |
272 |
101.1 |
(99.8, 102.4) |
0.965 |
1.000 |
0.489 |
| FEV1/FVC, mean, 95% CI |
45 |
84.6 |
(82.7, 86.5) |
126 |
85.3 |
(83.9, 86.6) |
272 |
84.9 |
(84.1, 85.7) |
1.000 |
1.000 |
0.482 |
| FEF25–75%, mean, 95% CI |
45 |
84.9 |
(79.4, 90.3) |
126 |
89.6 |
(85.9, 93.4) |
272 |
87.4 |
(85.1, 89.6) |
1.000 |
0.827 |
0.317 |
| FEF25–75/FVC, mean, 95% CI | 45 | 54.5 | (50.0, 59.0) | 126 | 57.3 | (54.7, 59.9) | 272 | 55.7 | (54.1, 57.4) | 1.000 | 0.906 | 0.429 |
Abbreviations:FU1 first follow-up at the ages of 10.8 years (girls) and 11.8 years (boys), FU2 second follow-up at the age of 12.8 years (both genders), FEV 1 % forced expiratory volume in first second predicted, CI Confidence interval, FVC% forced vital capacity predicted, FEF 25–75 % forced expiratory flow between 25% and 75% of the forced vital capacity, predicted.
a)Pearson’s exact chi-square test (dichotomous variable) and one way analysis of variance (continuous variable) with Bonferroni corrections;
b)Cochran-Armitage test for dichotomous outcomes and one way analysis of variance for continuous outcomes;
c)Sum of specific IgE > 3.9 kU/l.